Jonathan D. Licht, MD

Jonathan Licht_MCM_0473Jonathan D. Licht, MD
Director, UF Health Cancer Center
Department of Medicine
Department of Biochemistry and Molecular Biology
Marshall E. Rinker Sr. Foundation and David B and Leighan R. Rinker Chair
PO Box 103633
Gainesville, FL 32610


Jonathan D. Licht, MD, is the Director of the University of Florida Health Cancer Center, holding the Marshall E. Rinker, Sr. Foundation and David B. and Leighan R. Rinker Chair.  Previously Dr. Licht was Chief of Hematology/Oncology at Northwestern University and an Associate Director of the Robert H. Lurie Comprehensive Cancer Center.

Dr. Licht’s laboratory studies aberrant gene regulation, specifically the role of abnormal function of histone methyl transferases and histone demethyalses in diseases such as multiple myeloma and is developing small molecule strategies to normalize gene regulation and treat disease.

NCI funded for nearly 25 years, Dr. Licht is also Principal Investigator of a Leukemia and Lymphoma Society Specialized Center and a Multiple Myeloma Research Foundation program grant both in epigenetics.  He is an investigator in the Dana-Farber SPORE in myeloma and co-leader in a NCI-funded Chicago Physical Sciences Oncology Center.  Dr. Licht is a Senior Editor of Clinical Cancer Research and serves on the editorial boards of Oncogene and Cancer Cell. Dr. Licht is a member of the executive committee of the American Society of Hematology, and will be co-director of the 2017 ASH/EHA Translational Research Training program.  Additionally he sits on the Medical/Scientific Board of the LLS and is a member of the Basic Mechanisms of Cancer Therapeutics Study Section.  Dr. Licht has published nearly 170 original articles, reviews and book chapters. Dr. Licht has mentored over 40 graduate students and postdoctoral fellows and 20 faculty members.




MD Columbia University College of Physician and Surgeons Medicine
Residency Beth Israel Hospital, Harvard Medical School Internal Medicine
Fellowship Dana-Farber Cancer Institute, Harvard Medical School Medical Oncology
Postdoctoral Fellowship Dana-Farber Cancer Institute, Harvard Medical School Eukaryotic Transcription


  • Nabet B, Ó Broin P, Shieh K, Lin CY Will CM, Popovic R, Ezponda T, JBradner JA, Golden AA,  Licht JD.  Deregulation of the Ras-Erk signaling Axis Modulates the Enhancer Landscape. Cell Reports.  pii: S2211-1247(15)00822-0.
  • Popovic R, Martinez-Garcia E, Giannopoulou E, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC, Hua Y, Bulic M, Jiang Y, Carrara M, Calogero RA, Kath W, Kelleher NL, Wang JP, Elemento E, Licht JD. Histone Methyltransferase MMSET Alters EZH2 Binding and Reprograms the Myeloma Epigenome Through Global and Focal Changes in H3K36 and H3K27 Methylation. PLoS Genet. 10(9):e1004566. doi: 10.1371/journal.pgen.1004566. 2014
  • Small EC, Xi L, Wang JP, Widom J, Licht JD.  Single Cell Nucleosome Mapping Reveals the Molecular Basis of Gene Expression Heterogeneity.  Proc Natl Acad Sci, USA. 111:E2462-71, 2014.
  • Oyer JA, Huang X, Zhen Y, Shim J, Ezponda T, Allegretta M, Okot-Kotbr CI, Patel JP, Melnick A, Levine RL, Ferrando A, MacKerell Jr AD, Kelleher NL, Licht JD, Popovic R. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies- Leukemia. 2014 Jan;28:198-201, 2014
  • Béguelin W, Popovic R, Teater M,  Jiang Y, Bunting K, Garcia M, Shen H, Yang SN; Wang L, Ezponda T, Martinez-Garcia E, ; Zhang H, Zhang Y, Verma S, McCabe M, Ott H, Van Aller G, Kruger R, Liu Y, McHugh C, Scott D, Chung YR, Kelleher N, Shaknovich R, Creasy C, Gascoyne R, Wong K-K, Cerchietti L, Levine R, Abdel-Wahab O, Licht JD*, Elemento O*, Melnick A*. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell  23:677-92, 2013.

Please click here for a list of Dr. Licht’s industry relationships.